F.D.A. Nominee Faces Steep Climb to Senate Confirmationnews2022-02-03T17:31:17+00:00February 3rd, 2022|The New York Times|
F.D.A. Approves Remdesivir for Patients Not Hospitalizednews2022-01-22T16:58:04+00:00January 22nd, 2022|The New York Times|
Senate Panel OKs Califf Nomination for F.D.A. Chiefnews2022-01-14T04:32:55+00:00January 14th, 2022|The New York Times|
F.D.A. Plans to Allow 12- to 15-Year-Olds to Receive Pfizer Boostersnews2021-12-31T02:43:34+00:00December 31st, 2021|The New York Times|
Merck’s Covid Pill Is Authorized by F.D.A. for High-Risk Adultsnews2021-12-24T02:19:46+00:00December 24th, 2021|The New York Times|
Beneath a Covid Vaccine Debacle, 30 Years of Government Culpabilitynews2021-12-23T10:00:26+00:00December 23rd, 2021|The New York Times|
Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces Obstaclesnews2021-12-21T02:08:14+00:00December 21st, 2021|The New York Times|
F.D.A. Will Permanently Allow Abortion Pills by Mailnews2021-12-17T00:37:15+00:00December 17th, 2021|The New York Times|
F.D.A. Will Permanently Allow Abortion Pills by Mailnews2021-12-17T00:37:15+00:00December 17th, 2021|The New York Times|
Senators Question Califf, the F.D.A. Nominee, on Opioid Crisis and Pandemic Responsenews2021-12-14T23:44:00+00:00December 14th, 2021|The New York Times|
